Dataset Information


Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.

ABSTRACT: BACKGROUND:The comparative efficacy of inhaled corticosteroid/long-acting muscarinic antagonist/long-acting ?2-agonist (ICS/LAMA/LABA) triple therapy administered via single or multiple inhalers in patients with chronic obstructive pulmonary disease (COPD) has not been evaluated comprehensively. We conducted two replicate trials comparing single- with multiple-inhaler ICS/LAMA/LABA combination in COPD. METHODS:207608 and 207609 were Phase IV, 12-week, randomized, double-blind, triple-dummy non-inferiority trials comparing once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25??g via Ellipta inhaler, with twice-daily budesonide/formoterol (BUD/FOR) 400/12??g via metered-dose inhaler plus once-daily tiotropium (TIO) 18??g via HandiHaler. Patients had symptomatic COPD and forced expiratory volume in 1?s (FEV1)


PROVIDER: S-EPMC7257245 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5934530 | BioStudies
2018-01-01 | S-EPMC5785849 | BioStudies
2018-01-01 | S-EPMC6168763 | BioStudies
2018-01-01 | S-EPMC5778187 | BioStudies
2017-01-01 | S-EPMC5702366 | BioStudies
1000-01-01 | S-EPMC5338844 | BioStudies
2020-01-01 | S-EPMC7607727 | BioStudies
2016-01-01 | S-EPMC4875926 | BioStudies
2020-01-01 | S-EPMC7444357 | BioStudies
2020-01-01 | S-EPMC7360413 | BioStudies